Preview

Ведомости Научного центра экспертизы средств медицинского применения

Расширенный поиск

Регуляторные подходы к оценке биоаналогов для лечения ревматических заболеваний

https://doi.org/10.30895/1991-2919-2017-7-3-155-163

Полный текст:

Аннотация

Рассмотрены вопросы планирования программ разработки биоаналогичных препаратов, которые применяют для терапии пациентов с ревматическими заболеваниями. Проанализированы основные определения биоаналогичных препаратов, применяемые в Российской Федерации и за рубежом, а также регуляторные подходы к признанию биоаналогичности. Описан дизайн подтверждающих клинических исследований. Отмечено, что обоснование границ эквивалентности должно строиться как на клинических, так и на статистических предпосылках. Обоснована необходимость постоянного совершенствования требований и подходов к оценке достаточности программ изучения этих препаратов.

Об авторах

Д. В. Горячев
НЦ экспертизы средств медицинского применения
Россия


М. Ю. Тельных
НЦ экспертизы средств медицинского применения
Россия


Н. Д. Бунятян
НЦ экспертизы средств медицинского применения
Россия


Список литературы

1. Федеральный закон Российской Федерации от 12 апреля 2010 г. № 61-ФЗ «Об обращении лекарственных средств». Available from: https://goo.gl/JgCdAv.

2. Государственный реестр лекарственных средств [Интернет]. Available from: https://grls.rosminzdrav.ru.

3. U. S. Food and Drug Administration. Biosimilars. Available from: https://goo.gl/Xy3HsL.

4. European Medicines Agency. Biosimilar Medicines. Available from: https://goo.gl/JxefFK.

5. Guidline on similar biological medicinal products. Available from: https://goo.gl/XdoSRo.

6. Taylor L. Over 700 biosimilars now in development worldwide: report. Pharma Times digital. 30 September, 2014. Available from: https://goo.gl/2hzMGT.

7. Guidelines on evaluation of similar biotherapeutic products. Available from: https://goo.gl/dFbGwD.

8. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014; 73(1): 198-206.

9. Woodcock J. Biosimilar implementation: a progress report from FDA. 2015. Available from: http://www.fda.gov/NewsEvents/Testimony/ucm463036.htm.

10. Federal Food, Drug and Cosmetic Act. Available from: https:// goo.gl/4xHjd7.

11. Public Health Service Act. Available from: https://legcounsel.house.gov/Comps/PHSA-merged.pdf.

12. Implementation of the Biologics Price Competition and Innovation Act of 2009. Available from: https://goo.gl/Ai3RUq.

13. Биоаналоги: вопросы и ответы относительно реализации Закона о ценовой конкуренции и инновациям биологических препаратов от 2009 г. [Интернет]. Available from: http://www.pharmadvisor.ru/document/tr3698.

14. Christl L. Biologics Price Competition and Innovation Act of 2009: FDA’s overview of the regulatory guidance for the development and approval of biosimilar products in the US. Available from: https:// goo.gl/iKfcq8.

15. Руководство по экспертизе лекарственных средств. Т. IV. M.: Полиграф-Плюс; 2014.

16. Goel N, Chance K. The biosimilar landscape: a systematic review of its current status. Arthritis Rheum. 2014; 66(Suppl 11): S662.

17. van Aerts LA, De Smet K, Reichmann G, van der Laan JW, Schneider CK. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union. MAbs 2014; 6(5): 1155-62.

18. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014; 16(1): 22-6.

19. Kimball AB, Leonardi C, Stahle M, Gulliwer W, Chevrier M, Fakharzadeh S, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014; 171(1): 137-47.

20. European Medicines Agency. Guideline on similar biological medicinal products. 2014. Available from: https://goo.gl/2X5hXM.

21. Schmitz S, Adams R, Walsh C. The use of continuous data versus binary data in MTC models: A case study in rheumatoid arthritis. BMC Med Res Methodol 2012; (12): 167.

22. Lai Z, La Noce A. Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. RMD Open 2016; 2(1): e000154.

23. Cohen SB, Genovese MC, Choy EH, Perez-Ruis F, Pablos JL, Zhang N, et al. Randomized, double-blind, phase 3 study of efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid arthritis. Available from: https://goo.gl/qAg3Mv.

24. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48(1): 35-45.

25. Press relies, April 5, 2016. FDA approves Inflectra, a biosimilar to Remicade. Available from: https://goo.gl/yrd6Em.

26. Grabowski D, Henderson B, Lam D, Keystone EC, Thorne C, Jamal S, et al. Attitudes towards subsequent entry biologics/biosimilars: a survey of Canadian rheumatologists. Clin Rheumatol 2015; 34(8): 1427-33.

27. Australian approval for infliximab biosimilar. Available from: https://goo.gl/qzMJaT.

28. Wang J, Chow S-C. On the regulatory approval pathway of biosimilar products. Pharmaceuticals 2012; 5(4): 353-68.

29. Press relies, April 5, 2016. FDA approves Inflectra, a biosimilar to Remicade. Available from: https://goo.gl/cfrX4X.

30. Title VII: Improving access to innovative medical therapies. Subtitle A: Biologic Price Competition and Innovation. 2010. Available from: https://goo.gl/qswQeT.

31. Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohn’s Colitis 2013; 7(7): 586-9.

32. Rompas S, Goss T, Amanuel S, Coutino V, Lai Z, Antonini P, et al. Demonstrating value for biosimilars: a conceptual framework. Am Health Drug Benefits 2015; 8(3): 129-39.

33. Teixeira FV. First biosimilar of infliximab approved in Brazil: response from the Brazilian IBD society. GaBI Journal 2016; 5(1): 4-5.

34. Murphy C, Sugrue K, Mohamad G, McCarthy J, Buckley M. Biosimilar but not the same. J Crohn’s Colitis 2015; 9(Suppl 1): S331-2.

35. U. S. Food and Drug Administration. Draft guidance for industry. Non-inferiority clinical trials. 2016. Available from: https://goo.gl/ csfW1o.

36. European Medicines Agency. Guideline on the choice of the non-inferiority margin. 2005. Available from: https://goo.gl/nc39WD.

37. Grabowski D, Henderson B, Lam D, Keystone EC, Thorne C, Jamal S, et al. Attitudes towards subsequent entry biologics/biosimilars: a survey of Canadian rheumatologists. Clin Rheumatol 2015; 34(8): 1427-33.

38. Колесникова ЕЮ. Фармакоэпидемиологическое исследование нежелательных реакций при применении разрабатываемых лекарственных средств. Безопасность и риск фармакотерапии 2014; 3(4): 27-30.

39. ICH E10. Harmonised Tripartite Guideline: Choice of Control Group and Related Issues in Clinical Trials E10. 20 July 2000. Available from: https://goo.gl/WTDtYQ.

40. ICH E9. Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9. 5 Feb 1997. Available from: https://goo.gl/AUtbxi.

41. Руководство по проведению клинических исследований лекарственных средств. Ч. 1. М.: Гриф и К; 2013.

42. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis. 2013; 72(10): 1589-93.

43. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J. Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194): 1932-9.

44. Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017; 76(1): 58-64.

45. Emery P, Vencovsky, J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017; 76(1): 51-7.

46. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, et al. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. 2016; 19(11): 1157-68.

47. Kay J, Chopra A, Chandrashekara S, Wyand M. OP0012 A Phase 3, randomized, double-blind, active comparator study of the efficacy and safety of Bow015, a biosimilar Infliximab, in patients with active rheumatoid arthritis on stable Methotrexate doses. Ann Rheum Dis. 2014; 73(Suppl 2): 64.


Для цитирования:


Горячев Д.В., Тельных М.Ю., Бунятян Н.Д. Регуляторные подходы к оценке биоаналогов для лечения ревматических заболеваний. Ведомости Научного центра экспертизы средств медицинского применения. 2017;7(3):155-163. https://doi.org/10.30895/1991-2919-2017-7-3-155-163

For citation:


Goryachev D.V., Telnykh M.Y., Bunyatyan N.D. Regulatory approaches to evaluation of biosimilars for treatment of rheumatic diseases. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2017;7(3):155-163. (In Russ.) https://doi.org/10.30895/1991-2919-2017-7-3-155-163

Просмотров: 25


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1991-2919 (Print)
ISSN 2619-1172 (Online)